Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 768

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 768
---
 not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. /s/ PricewaterhouseCoopers AG Zurich, Switzerland May 15, 2024, except for the effects of the reverse share split discussed in Note 2 to the consolidated financial statements, as to which the date is May 16, 2025 We served as the Company’s auditor from 2021 to 2024. Annex F-3

NLS PHARMACEUTICS LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

| ASSETS                                                                                                                                                
 Current assets:                                                                                                                                       |     | December 31, 
 2024         
 Restated     |             |   |     | 2023 |             |   |
|:------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:-------------|------------:|:--|:----|:-----|------------:|:--|
| Cash and cash equivalents                                                                                                                             |     | $            |   1,665,395 |   |     | $    |     897,680 |   |
| Prepaid expenses and other current assets (Note 3)                                                                                                    |     |              |     560,157 |   |     |      |     925,382 |   |
| Total current assets